FibroGen
IPOLanding Page | Kyntra Bio
Public · San Francisco, United States · Founded 1993 · $211.5M raised
- Headquarters
- San Francisco, California
- Employees
- 11–50
- Founded
- 1993
- Business Model
- B2B
- Website
- fibrogen.com
- Total Funding
- $211.5M
- Last Round
- $62.0M Series FNov 2014
- Rounds
- 6
- Type
- Public
About
FibroGen (now operating as Kyntra Bio) is a biopharmaceutical company developing first-in-class medicines for life-threatening conditions, with a pipeline focused on anemia associated with lower-risk myelodysplastic syndrome and metastatic castration-resistant prostate cancer. Its lead programs include roxadustat, an oral HIF-PHI approved in multiple regions for anemia in chronic kidney disease, and FG-3246, an antibody-drug conjugate targeting prostate cancer.
Summary
FibroGen is a Biotech company based in San Francisco, United States, founded in 1993. It has raised $211.5M in total across 6 rounds, most recently a $62.0M Series F round in Nov 2014. Investors include American Express Financial and Unknown.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Nov 2014
Sign up to see all 7 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...